Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1371 • ACR Convergence 2023
Are Ultrasound Salivary Parenchymal Abnormalities More Severe in Primary Sjögren Patients with a Higher Disease Duration ? A Cross-sectional International Study
Alice TISON¹, sandrine jousse joulin², Maëlys Consigny³, Philipp Moog⁴, Benedikt Hofauer⁵, Eric Hachulla⁶, Christophe Lamotte⁷, JACQUES MOREL⁸, Gael Mouterde⁹, Vera Milic¹⁰, Hendrika Bootsma¹¹, Alja Stel¹², Benjamin A Fisher¹³, Mark Maybury¹⁴, Alan Baer¹⁵, Dana Direnzo¹⁶, Hae-Rim Kim¹⁷, Hong Ki Min¹⁸, Shin-Seok Lee¹⁹, Sung-Eun Choi¹⁹, Guillermo CARVAJAL ALEGRIA²⁰, Sylvie Boisramé²¹, Dewi Guellec²², Divi Cornec²³, Malin Jonsson²⁴, Daniel Hammenfors²⁵, Alain SARAUX²⁶ and Valerie Devauchelle²⁷, ¹CHU de la Cavale Blanche, Brest, France, ²Rheumatology, CHU Brest, Brest, France, ³Biostatistics, CHU Brest, Brest, France, ⁴Rheumatology, CHU Munich, Munich, Germany, ⁵Otolaryngology, CHU Munich, Munich, Germany, ⁶University of Lille, Lille, France, ⁷Internal Medicine and Clinical Immunology, CHU Lille, Lille, France, ⁸Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ⁹CHU Lapeyronie, Montpellier, France, ¹⁰Rheumatology, University of Belgrade, Medical School, Belgrade, Serbia, ¹¹Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ¹²Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands, ¹³University of Birmingham, Birmingham, United Kingdom, ¹⁴Rheumatology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶University of Pennsylvania, Bala Cynwyd, PA, ¹⁷Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁸Konkuk University School of Medicine, Seoul, South Korea, ¹⁹Chonnam National University Medical School & Hospital, Gwangju, South Korea, ²⁰CHRU de Tours, Tours, France, ²¹Ondontology, CHU Brest, France, Brest, France, ²²CHU de Brest, Brest, France, ²³University of Brest, Brest, France, ²⁴Clinical dentistry, University of Bergen, Bergen, Norway, Bergen, Norway, ²⁵Rheumatology, Haukeland University Hospital, Bergen, Norway, ²⁶CHU Brest, Brest, France, ²⁷UBO, Brest, France
Background/Purpose: Salivary gland ultrasonography (SGUS) is commonly used in primary Sjögren Disease (pSD) as a diagnostic tool. It could also be used to monitor disease…
Abstract Number: 1636 • ACR Convergence 2023
Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
E. William St. Clair¹, Liangwei Wang², Ilias Alevizos², William A. Rees², Alan Baer³, Wan-Fai Ng⁴, Ghaith Noaiseh⁵ and Chiara Baldini⁶, ¹Duke University Medical Center, Durham, NC, ²Horizon Therapeutics, Rockville, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵University of Kansas Medical Center, Kansas City, KS, ⁶University of Pisa, Pisa, Italy
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 2188 • ACR Convergence 2023
Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis
Regis Sewa Marques, Maria Fernanda Zacarin, Pamela Bellini, Raissa Dudienas D Pereira, Aloma Guinami Scabora, Zoraida Sachetto, Manoel Bertolo and ALISSON PUGLIESI, Universidade Estadual de Campinas, Campinas, Brazil
Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
Abstract Number: 1372 • ACR Convergence 2023
Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab
Mathilde Pezot¹, Gaetane Nocturne², Rakiba Belkhir¹, Julien Henry¹, Stephan Pavy¹, Raphaele Seror³, Xavier Mariette⁴ and Samuel Bitoun⁵, ¹Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, ²APHP, Le Kremlin-Bicêtre, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁵CHU Bicêtre APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Among patients with auto-immune diseases (AID) treated with Rituximab (RTX), anti-drug antibodies (ADAb) leading to inefficacy and infusion reactions (Wincup and al., Ann Rheum…
Abstract Number: 1637 • ACR Convergence 2023
IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity
Helena Achten¹, Liselotte Deroo², Kristel De Boeck³, Matthias Jarlborg¹, Tine Decruy¹, Joke Deprez¹, Emilie Dumas¹, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Ghent, Belgium, ²Ghent University, Gent, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵University Hospital Ghent, Ghent, Belgium
Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…
Abstract Number: 2189 • ACR Convergence 2023
Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement
Giovanni Fulvio¹, Matilde Bandeira², Augusto Silva³, Gaetano La Rocca⁴, Silvia Fonzetti⁵, Francesco Ferro⁶, Marta Mosca⁷, Vasco Romão², Chiara Baldini¹, Manuel Silvério-António⁸ and Nikita Khmelinskii², ¹University of Pisa, Pisa, Italy, ²Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ³Santa Maria Hospital, Maceira, Portugal, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵AOUP, Pisa, Italy, ⁶Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁷Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁸Hospital Santa Maria, Lisboa, Portugal
Background/Purpose: Sjogren's disease (SjD) is characterized by a moderate prevalence of cytopenia, mainly neutropenia and lymphocytopenia with a typical fluctuating pattern. The associations between clinical…
Abstract Number: 0581 • ACR Convergence 2023
Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases
Daphne Bijlsma, Ewa Lukasik, Michael Hausmann, Gerber Gomez, Christine Ginocchio and Emmanuel Moreau, Quotient Suisse SA, Eysins, Switzerland
Background/Purpose: Detection of autoantibodies is key for the identification and prognosis of patients with connective tissue diseases (CTD); however, some current testing methods are manual,…
Abstract Number: 1373 • ACR Convergence 2023
Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome
Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Deltex1 is a transcription target of nuclear factor of activated T cells in mice and promotes T cell anergy. We have previously reported that…
Abstract Number: 1638 • ACR Convergence 2023
CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden
Tuyet-Hang Pham¹, Michael A. Smith¹, Nannette Mittereder¹, William A. Rees², Ilias Alevizos², E. William St. Clair³ and Claire Emson¹, ¹Horizon Therapeutics plc, Rockville, MD, ²Horizon Therapeutics, Rockville, MD, ³Duke University Medical Center, Durham, NC
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 2190 • ACR Convergence 2023
Saliclick: A Novel Technology for Minimal Invasive Salivary Gland Biopsy in Suspected Sjögren’s Syndrome
Thomas Hügle¹, Diana Dan² and Alexandre Dumusc³, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland, ²Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ³Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Switzerland, Lausanne, Switzerland
Background/Purpose: Labial minor salivary gland (MSG) biopsy is a major element in the diagnosis of Sjögren´s Syndrome and the exclusion of other pathologies, respectively. Transient…
Abstract Number: 0802 • ACR Convergence 2023
Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells
Samuel Kemble¹, Christopher Mahony², Charlotte Smith², Joel Rurik³, Haig Aghajanian³, Jonathan Epstein³, Mark Coles⁴ and Adam Croft², ¹University Birmingham, Rugeley, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
Abstract Number: 1374 • ACR Convergence 2023
Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Marco Sprecher¹, Florine Weber², Kastriot Kastrati³, Helmut Prosch⁴, Natasha Moe⁵, Emily Langballe⁶, Cosimo Bruni⁷, Oyvind Molberg⁸, Phuong Phuong Diep⁹, Christian Clarenbach¹⁰, Paul Studenic¹¹, Helena Andersson⁸, Oyvind Midtvedt¹², Torhild Garen⁸, Karoline Lerang¹³, Thomas Frauenfelder¹⁴, Helga Radner¹⁵, Oliver Distler⁷ and Anna Maria Hoffmann-Vold¹⁶, ¹Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ⁴Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁵Dept of Radiology, University Hospital Oslo, Oslo, Norway, ⁶Universitetet i Oslo, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹¹Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁴Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁵Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁶Oslo University Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…
Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Verónica Pulito-Cueto¹, David Iturbe-Fernández², Victor Mora-Cuesta², Joao Carlos Batista-Liz¹, Belén Atienza-Mateo³, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Miguel A Gonzalez-Gay⁴, Jose Cifrian⁵, Ricardo Blanco¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
Abstract Number: 2191 • ACR Convergence 2023
Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease
Gaetane Nocturne¹, Mathilde di Filippo², Oriane Marmontel², Pascale Chretien¹, Roman Krzysiek¹, François Lifermann³, Nawal Rahal¹, Rakiba Belkhir⁴, Philippe Moulin² and Xavier Mariette⁵, ¹APHP, Le Kremlin-Bicêtre, France, ²Hospices Civils de Lyon, Lyon, France, ³Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, ⁴Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, ⁵Université Paris-Saclay, Le Kremlin-Bicêtre, France
Background/Purpose: Sjögren's disease (Sjo) is a systemic autoimmune disease. In 80% of the patients, Sjo is responsible for dryness, fatigue, and joint pain. In 10%…

« Previous Page
1
…
5
6
7
8
9
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].